The clinical potential of HMGB1 for the risk assessment of severe checkpoint inhibitor pneumonitis: A prospective multicenter study (CS-Lung004)
European Journal of Cancer · 2025
DOI: 10.1016/j.ejca.2025.115606 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Journal of Cancer, 2025. Verfasst von Kakuhiro Yamaguchi und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Hiroshima University Hospital, Japan. Electronic address: yamaguchikakuhiro@gmail.com. Hauptthemen laut MEDLINE: HMGB1 Protein, Immune Checkpoint Inhibitors, Pneumonia, Lung Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory Medicine, Hiroshima University Hospital, Japan. Electronic address: yamaguchikakuhiro@gmail.com.
- Department of Respiratory Internal Medicine, Hiroshima City Hiroshima Citizens Hospital, Japan.
- Department of Internal Medicine, Division of Hematology, Rheumatology, and Respiratory Medicine, Faculty of Medicine, Kagawa University, Japan.
- Department of Molecular and Internal Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, Japan.
- Department of Respiratory Medicine, Hiroshima Red Cross Hospital & Atomic-Bomb Survivors Hospital, Japan.
- Department of Respiratory Medicine, National Hospital Organization Higashi-Hiroshima Medical Center, Japan.
Förderung
- Japan Agency for Medical Research and Development
Zitieren
APA
Yamaguchi, K., Takao, S., Kanaji, N., Hirakawa, T., Matsumoto, N., Miyazaki, K., Okimoto, T., Ando, C., Higo, H., Yanai, M., Nagasaki, Y., Kurose, K., Watanabe, M., Oyama, K., Toyoda, Y., Ono, S., Tada, S., Iwamoto, H., & Hattori, N. (2025). The clinical potential of HMGB1 for the risk assessment of severe checkpoint inhibitor pneumonitis: A prospective multicenter study (CS-Lung004). European Journal of Cancer. https://doi.org/10.1016/j.ejca.2025.115606
Vancouver
Yamaguchi K, Takao S, Kanaji N, Hirakawa T, Matsumoto N, Miyazaki K, et al. The clinical potential of HMGB1 for the risk assessment of severe checkpoint inhibitor pneumonitis: A prospective multicenter study (CS-Lung004). European Journal of Cancer. 2025. doi:10.1016/j.ejca.2025.115606
BibTeX
@article{Yamaguchi2025,
author = {Yamaguchi, Kakuhiro and Takao, Shun and Kanaji, Nobuhiro and Hirakawa, Tetsu and Matsumoto, Naoko and Miyazaki, Kozue and Okimoto, Tamio and Ando, Chihiro and Higo, Hisao and Yanai, Masaaki and Nagasaki, Yasunari and Kurose, Koji and Watanabe, Masako and Oyama, Kosuke and Toyoda, Yuko and Ono, Sachie and Tada, Shinpei and Iwamoto, Hiroshi and Hattori, Noboru},
title = {The clinical potential of HMGB1 for the risk assessment of severe checkpoint inhibitor pneumonitis: A prospective multicenter study (CS-Lung004)},
journal = {European Journal of Cancer},
year = {2025},
doi = {10.1016/j.ejca.2025.115606}
}
EUVIMED